Sunshine Biopharma Inc
NASDAQ:SBFM

Watchlist Manager
Sunshine Biopharma Inc Logo
Sunshine Biopharma Inc
NASDAQ:SBFM
Watchlist
Price: 1.46 USD 1.39% Market Closed
Market Cap: 7.2m USD

SBFM's latest stock split occurred on Aug 8, 2024

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, SBFM traded at 0.1526 per share. Afterward, the share price was about 2.9714.

The adjusted shares began trading on Aug 8, 2024. This was SBFM's 5th stock split, following the previous one in Apr 17, 2024.

Last Splits:
Aug 8, 2024
1-for-20
Apr 17, 2024
1-for-100
Feb 9, 2022
1-for-200
Apr 6, 2020
1-for-20
Feb 1, 2019
1-for-20
Pre-Split Price
3.052 0.1526
Post-Split Price
2.9714
Before
After
Last Splits:
Aug 8, 2024
1-for-20
Apr 17, 2024
1-for-100
Feb 9, 2022
1-for-200
Apr 6, 2020
1-for-20
Feb 1, 2019
1-for-20

Sunshine Biopharma Inc
Stock Splits History

SBFM Stock Splits Timeline
Aug 8, 2024
Aug 8, 2024
Split 1-for-20
/0.05
Pre-Split Price
3.052 0.1526
Post-Split Price
2.9714
Before
After
Apr 17, 2024
Apr 17, 2024
Split 1-for-100
/0.01
Pre-Split Price
136 0.068
Post-Split Price
76
Before
After
Feb 9, 2022
Feb 9, 2022
Split 1-for-200
/0.005
Pre-Split Price
17 760 8.88
Post-Split Price
17 760
Before
After
Apr 6, 2020
Apr 6, 2020
Split 1-for-20
/0.05
Pre-Split Price
2 400 1.2
Post-Split Price
2 820.0004
Before
After
Feb 1, 2019
Feb 1, 2019
Split 1-for-20
/0.05
Pre-Split Price
144 000 72
Post-Split Price
160 000
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.22 45.22 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
62.79 62.79 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Sunshine Biopharma Inc
Glance View

Market Cap
6.7m USD
Industry
Biotechnology

Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. The company is headquartered in Pointe-Claire, Quebec and currently employs 3 full-time employees. The company went IPO on 2008-08-15. In addition, the Company is engaged in the development and commercialization of science-based nutritional supplements. The Company’s drug development operations include SBFM-PL4 Anti-Coronavirus Treatment and Adva-27a Anticancer Drug. The firm is engaged in the development of its Anti-Coronavirus compound, SBFM-PL4. The company is advancing the development of two compounds in parallel with its SBFM-PL4. The Company’s drug development activities have focused on the development of a small molecule, Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells, including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells.

SBFM Intrinsic Value
11.67 USD
Undervaluation 87%
Intrinsic Value
Price
Back to Top